Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at [email protected]

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
Stocks mentioned in the article
ChangeLast1st jan.
BANK OF AMERICA -0.17% 30.14 Delayed Quote.2.71%
IMMUNOMEDICS, INC. 0.87% 16.22 Delayed Quote.-0.12%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
04/25Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone ..
GL
04/19IMMUNOMEDICS INC : Notice of Delisting or Failure to Satisfy a Continued Listing..
AQ
04/10IMMUNOMEDICS INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/09IMMUNOMEDICS : Appoints Dr. Robert Iannone Head of Research & Development and Ch..
AQ
04/02IMMUNOMEDICS INC : Submission of Matters to a Vote of Security Holders (form 8-K..
AQ
03/05Immunomedics to Present at Cowen and Company 38th Annual Health Care Conferen..
GL
02/16IMMUNOMEDICS : to Participate in RBC Capital Markets 2018 Global Healthcare Conf..
AQ
02/15Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Con..
GL
02/12IMMUNOMEDICS : DLA Piper Advises Immunomedics on Royalty Funding and Stock Purch..
AQ
02/09IMMUNOMEDICS : reports 2Q loss
AQ
More news
News from SeekingAlpha
04/23READER INQUIRY : Is There Further Upside In Immunomedics? 
02/09Immunomedics' (IMMU) Q2 2018 Results - Earnings Call Transcript 
02/08Immunomedics beats by $0.10, misses on revenue 
01/123 THINGS IN BIOTECH YOU SHOULD LEARN : January 12, 2018 
01/12Immunomedics (IMMU) Presents At 36th Annual J.P. Morgan Healthcare Conference.. 
Financials ($)
Sales 2018 9,93 M
EBIT 2018 -124 M
Net income 2018 -159 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 269x
Capi. / Sales 2019 65,1x
Capitalization 2 676 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 22,3 $
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Michael Pehl President & Chief Executive Officer
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
Robert Iannone Chief Medical Officer, Head-Research & Development
David M. Goldenberg Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.-0.12%2 676
CELLTRION, INC.--.--%28 789
IQVIA HOLDINGS INC-1.18%20 413
LONZA GROUP-7.22%18 571
INCYTE CORPORATION-28.05%14 432
NEKTAR THERAPEUTICS41.51%13 751